NCT07783607Not yet recruiting
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma
A Pilot Feasibility Study of Oncology-Embedded Versus Primary Care-Directed Cardiovascular Risk Assessment in Adults With Multiple Myeloma Starting a New Line of Therapy
Source: ClinicalTrials.gov · Last updated 25 Aug 2026
Brief summary (registry, in English)
People with multiple myeloma may have health conditions or receive treatments that increase their risk of heart and blood-vessel problems. This pilot study will evaluate whether a structured heart-health assessment can be completed successfully and on time when adults with multiple myeloma start a new line of treatment. Participants who do not require urgent treatment in the hospital will be assigned by chance to receive the assessment from either an internal medicine clinician working with the oncology team or their primary care provider. Participants who require urgent inpatient treatment will receive the oncology-embedded assessment during their hospital stay. Researchers expect that both approaches will be practical, but the approaches may differ in how often and how quickly the assessments are completed. The study will also collect information about care recommendations, quality of life, physical activity, diet, usual-care blood test and electrocardiogram results, and heart-related health events. Because this is a small pilot study, it is not designed to determine whether one approach provides better health outcomes than the other.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 33 (estimated)
- First submitted
- 20 Aug 2026
- Start date
- 1 Feb 2028
- Primary completion date
- 1 Mar 2028
- Lead sponsor
- University of Vermont Medical Center
- Diseases
- Multiple myeloma
- NCT number
- NCT07783607
What you commit to
- Study type: Interventional
- Planned participants: 33
- From 1 Feb 2028 to the primary completion date, 1 Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- An acute cardiovascular condition requiring emergency evaluation or specialty cardiology management rather than routine cardiovascular risk assessment, as determined by the treating clinician.
- Any condition that, in the investigator's judgment, would prevent meaningful participation in the study intervention or required assessments.
Other
- Hospitalization or an urgent need to begin multiple myeloma treatment is not an exclusion.
- Participants meeting the urgent-treatment criteria may enroll in the separate nonrandomized urgent-treatment cohort.
Who the study is looking for
- Confirmed diagnosis of multiple myeloma.
- Age 18 years or older.
- Preparing to begin a new line of systemic multiple myeloma treatment in the newly diagnosed or relapsed or refractory setting.
- Planned ongoing oncology care with anticipated clinical visits sufficient to coordinate study assessments at Months 3, 6, and 12.
- For participants eligible for randomization, an established primary care provider who can be identified at enrollment and contacted by the study team if the participant is assigned to the primary care provider-directed pathway.
- Ability to understand the study and willingness to provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Vermont Medical Center Coordinator of this site? Confirm its status | Burlington | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.